These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

260 related items for PubMed ID: 29134562

  • 1. SEOM clinical guidelines for the treatment of metastatic prostate cancer (2017).
    Cassinello J, Arranz JÁ, Piulats JM, Sánchez A, Pérez-Valderrama B, Mellado B, Climent MÁ, Olmos D, Carles J, Lázaro M.
    Clin Transl Oncol; 2018 Jan; 20(1):57-68. PubMed ID: 29134562
    [Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3. Cabazitaxel for Hormone-Relapsed Metastatic Prostate Cancer Previously Treated With a Docetaxel-Containing Regimen: An Evidence Review Group Perspective of a NICE Single Technology Appraisal.
    Kearns B, Pandor A, Stevenson M, Hamilton J, Chambers D, Clowes M, Graham J, Kumar MS.
    Pharmacoeconomics; 2017 Apr; 35(4):415-424. PubMed ID: 27770303
    [Abstract] [Full Text] [Related]

  • 4. Metastatic castration resistant prostate cancer: current strategies of management in the Middle East.
    Bazarbashi S, Bachour M, Bulbul M, Alotaibi M, Jaloudi M, Jaafar H, Mukherji D, Farah N, Alrubai T, Shamseddine A.
    Crit Rev Oncol Hematol; 2014 Apr; 90(1):36-48. PubMed ID: 24289901
    [Abstract] [Full Text] [Related]

  • 5. Dutch Economic Value of Radium-223 in Metastatic Castration-Resistant Prostate Cancer.
    Peters ML, de Meijer C, Wyndaele D, Noordzij W, Leliveld-Kors AM, van den Bosch J, van den Berg PH, Baka A, Gaultney JG.
    Appl Health Econ Health Policy; 2018 Feb; 16(1):133-143. PubMed ID: 28866822
    [Abstract] [Full Text] [Related]

  • 6. New and emerging agents for the treatment of castration-resistant prostate cancer.
    Higano CS, Crawford ED.
    Urol Oncol; 2011 Feb; 29(6 Suppl):S1-8. PubMed ID: 22074657
    [Abstract] [Full Text] [Related]

  • 7. Current management of advanced and castration resistant prostate cancer.
    Gomella LG, Petrylak DP, Shayegan B.
    Can J Urol; 2014 Apr; 21(2 Supp 1):1-6. PubMed ID: 24775717
    [Abstract] [Full Text] [Related]

  • 8. Expert opinion on chemotherapy use in castration-resistant prostate cancer progressing after docetaxel.
    Gallardo E, Arranz JÁ, Maroto JP, León LÁ, Bellmunt J.
    Crit Rev Oncol Hematol; 2013 Nov; 88(2):357-67. PubMed ID: 23867574
    [Abstract] [Full Text] [Related]

  • 9. New treatment options for patients with metastatic prostate cancer.
    Snoeks LL, Ogilvie AC, van Haarst EP, Siegert CE.
    Neth J Med; 2013 Nov; 71(6):290-4. PubMed ID: 23956309
    [Abstract] [Full Text] [Related]

  • 10. Prostate cancer perspectives after chaarted: Optimizing treatment sequence.
    Estévez SV, Herranz UA, Calvo OF, Afonso Afonso FJ, Couto LS, Quintela ML, Mateos LL, Maciá Escalante S.
    Crit Rev Oncol Hematol; 2016 Nov; 107():119-127. PubMed ID: 27823639
    [Abstract] [Full Text] [Related]

  • 11. Novel agents for castration-resistant prostate cancer: Early experience and beyond.
    Fujimoto N.
    Int J Urol; 2016 Feb; 23(2):114-21. PubMed ID: 26311471
    [Abstract] [Full Text] [Related]

  • 12. New agents for the management of castration-resistant prostate cancer.
    Cersosimo RJ.
    Ann Pharmacother; 2012 Nov; 46(11):1518-28. PubMed ID: 23136351
    [Abstract] [Full Text] [Related]

  • 13. Emerging and second line therapies for the management of metastatic castration-resistant prostate cancer: the Australian perspective.
    Parente P, Parnis F, Gurney H.
    Asia Pac J Clin Oncol; 2012 Mar; 8(1):31-42. PubMed ID: 22369442
    [Abstract] [Full Text] [Related]

  • 14. New perspectives in the therapy of castration resistant prostate cancer.
    Rescigno P, Buonerba C, Bellmunt J, Sonpavde G, De Placido S, Di Lorenzo G.
    Curr Drug Targets; 2012 Dec; 13(13):1676-86. PubMed ID: 23043326
    [Abstract] [Full Text] [Related]

  • 15. [Modern treatment of metastatic hormone-sensitive prostate cancer].
    Küronya Z, Bíró K, Géczi L, Maráz A.
    Orv Hetil; 2018 Oct; 159(41):1664-1671. PubMed ID: 30295043
    [Abstract] [Full Text] [Related]

  • 16. Disease and Treatment Characteristics of Men Diagnosed With Metastatic Hormone-Sensitive Prostate Cancer in Real Life: Analysis From a Commercial Claims Database.
    Flaig TW, Potluri RC, Ng Y, Todd MB, Mehra M, Higano CS.
    Clin Genitourin Cancer; 2017 Apr; 15(2):273-279.e1. PubMed ID: 27876504
    [Abstract] [Full Text] [Related]

  • 17. Sequential use of novel therapeutics in advanced prostate cancer following docetaxel chemotherapy.
    Omlin A, Pezaro C, Gillessen Sommer S.
    Ther Adv Urol; 2014 Feb; 6(1):3-14. PubMed ID: 24489604
    [Abstract] [Full Text] [Related]

  • 18. Therapeutic opportunities for castration-resistant prostate cancer patients with bone metastases.
    Zustovich F, Fabiani F.
    Crit Rev Oncol Hematol; 2014 Aug; 91(2):197-209. PubMed ID: 24503416
    [Abstract] [Full Text] [Related]

  • 19. Radium-223 chloride: a new treatment option for metastatic castration-resistant prostate carcinoma.
    Pinto A, Cruz P.
    Drugs R D; 2012 Dec 01; 12(4):227-33. PubMed ID: 23190319
    [Abstract] [Full Text] [Related]

  • 20. Castration resistant prostate cancer (CRPC): state of the art, perspectives and new challenges.
    Massari F, Maines F, Modena A, Brunelli M, Bria E, Artibani W, Martignoni G, Tortora G.
    Anticancer Agents Med Chem; 2013 Jul 01; 13(6):872-86. PubMed ID: 23272970
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 13.